Skip to main content

Clene Inc.

corporate_fare Company Profile

Clene Inc.

CLNN·NASDAQ·Life Sciences·CIK 0001822791

We are a clinical-stage pharmaceutical company focused on discovering, developing, and selling new clean-surfaced nanotechnology ("CSN®") therapeutics. These CSN® therapeutics are made from transition element atoms that, when formed into nanocrystals, have unusually high and unique catalytic activities not found in the same elements in their bulk form. These activities support beneficial metabolic and energetic cellular reactions in diseased, stressed, and damaged cells. We believe our patented technology allows us to develop a wide range of CSN therapeutics for various diseases impacting human health. We developed an electro-crystal-chemistry drug development platform using advances in nanotechnology, plasma and quantum physics, materials science, and biochemistry. This platform creates nanocrystals with faceted structures and surfaces free of chemical modifications often found with other production methods, which can leave potentially toxic residues. Our method produces stable, non-toxic, and highly catalytic nanocrystals, overcoming a major challenge in using transition metal catalytic activity for therapy. Our clean-surfaced nanocrystals show catalytic activities many times higher than other commercially available nanoparticles we have evaluated. Our development and clinical efforts aim to transform the treatment of neurodegenerative diseases by restoring and protecting neuronal health and function. Our nanotherapeutics target cellular energy problems common to many diseases. We are currently focused on addressing significant unmet medical needs in central nervous system disorders, including amyotrophic lateral sclerosis ("ALS"), multiple sclerosis ("MS"), and Parkinson's disease ("PD"). Our drug development approach is innovation-focused and scientifically driven.

Clene Inc. (NASDAQ:CLNN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for CLNN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Clene Announces Strong Biomarker Data for ALS Drug CNM-Au8, Secures Key FDA Meeting for Accelerated Approval Pathway
  • Clene Inc. Secures $5.67M in Equity and Warrant Offering at Premium to Market, Addressing Going Concern

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$200K
Net Income
-$26.17M
Op. Cash Flow
-$18.55M
Free Cash Flow
-$18.59M
Gross Profit
$157K
Operating Income
-$23.08M
Cash & Equivalents
$5.19M
Total Debt
$17.79M
Debt / Equity
-1.01×
Net Margin
-130.87×
Shares Outstanding
10.85M sh
Source: 10-K · filed 2026-03-17 · accession 0001437749-26-008502
$3.59 +1.99% today
52-week range · as of 2026-11-04 $3.02 – $13.5
Market cap
$50.69M
Volume
144.1K (1.3× avg)
3-mo avg 107.7K
Live data · 2026-11-22 10:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CLNN - Filings & News (Page 3)

CLNN
Jan 12, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $3.59 info
Change: -$2.81 (-44%) info
Market Cap: $50.689M info
CLNN
Jan 09, 2026, 4:25 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $3.59 info
Change: -$2.80 (-44%) info
Market Cap: $50.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets